| abstract |
A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) 2-amide 1 - ({4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-) inhibitor compound ethyl (S) -pyrrolidin-1, 2-dicarboxylic acid (), pyridin-4-yl] -thiazol-2-yl} -amide or a pharmaceutically acceptable salt thereof, and (b) at least one protein inhibitor mitogen activated kinase (MEK) or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such a combination in the treatment of proliferative diseases; and methods for the treatment of a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. |